- Home
- DIAX vs MNMD Comparison
DIAX vs MNMD Comparison
Compare DIAX & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- MNMD
- Stock Information
- Founded
- DIAX 2005
- MNMD 2019
- Country
- DIAX United States
- MNMD United States
- Employees
- DIAX N/A
- MNMD N/A
- Industry
- DIAX Finance Companies
- MNMD Pharmaceuticals and Biotechnology
- Sector
- DIAX Finance
- MNMD Health Care
- Exchange
- DIAX Nasdaq
- MNMD Nasdaq
- Market Cap
- DIAX 523.0M
- MNMD 509.2M
- IPO Year
- DIAX N/A
- MNMD N/A
- Fundamental
- Price
- DIAX $14.33
- MNMD $9.64
- Analyst Decision
- DIAX
- MNMD Strong Buy
- Analyst Count
- DIAX 0
- MNMD 7
- Target Price
- DIAX N/A
- MNMD $26.29
- AVG Volume (30 Days)
- DIAX 96.6K
- MNMD 1.3M
- Earning Date
- DIAX 01-01-0001
- MNMD 08-12-2025
- Dividend Yield
- DIAX 7.93%
- MNMD N/A
- EPS Growth
- DIAX N/A
- MNMD N/A
- EPS
- DIAX N/A
- MNMD N/A
- Revenue
- DIAX N/A
- MNMD N/A
- Revenue This Year
- DIAX N/A
- MNMD N/A
- Revenue Next Year
- DIAX N/A
- MNMD N/A
- P/E Ratio
- DIAX N/A
- MNMD N/A
- Revenue Growth
- DIAX N/A
- MNMD N/A
- 52 Week Low
- DIAX $12.80
- MNMD $4.70
- 52 Week High
- DIAX $15.12
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- DIAX 54.01
- MNMD 72.96
- Support Level
- DIAX $14.17
- MNMD $8.06
- Resistance Level
- DIAX $14.38
- MNMD $10.24
- Average True Range (ATR)
- DIAX 0.11
- MNMD 0.47
- MACD
- DIAX -0.01
- MNMD 0.23
- Stochastic Oscillator
- DIAX 32.50
- MNMD 83.24
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).